Munich Cancer Registry



- Baseline statistics
- Selection Matrix
- ▶ Homepage

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

Year of diagnosis	1978-1987	1988-1997	1998-2011
Patients	701	1,629	7,371
Diseases	701	1,636	7,388
Creation date	04/01/2013		
Export date	01/03/2013		
Population	4.5 m		

C82-C85: NHL



http://www.tumorregister-muenchen.de/en/facts/surv/surv_C8285E.pdf




Figure 1a. Relative survival of patients with nHL by period of diagnosis. Included in the evaluation are 5,762 cases diagnosed between 1978 and 2011.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2009, and are represented by green diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Period of diagnosis 1978-1987 1988-1997 1998+ n=628 n=1,376 n=3,758 Years obs.% rel.% obs.% rel.% obs.% rel.% 0 100.0 100.0 100.0 100.0 100.0 100.0 1 83.3 85.2 81.2 83.2 77.6 79.9 2 72.6 75.7 73.3 76.7 69.8 73.4 3 66.2 70.5 67.7 72.5 65.9 70.8 4 60.8 66.0 63.8 69.7 61.7 67.8 5 55.0 60.9 58.3 65.2 58.1 65.3 6 50.4 56.7 54.6 62.2 54.9 62.9 7 45.9 52.7 51.6 60.0 51.9 60.6 8 42.7 49.9 47.4 56.3 46.4 56.4 10 37.9 45.9		-		<i>•</i> ••										
n = 1.376 $n = 3.758$ Yearsobs.%rel.%obs.%rel.%obs.%rel.%0100.0100.0100.0100.0100.0100.0100.0183.385.281.283.277.679.9272.675.773.376.769.873.4366.270.567.772.565.970.8460.866.063.869.761.767.8555.060.958.365.258.165.3650.456.754.662.254.962.9745.952.751.660.051.960.6842.749.947.456.349.859.4940.147.844.053.346.456.41037.945.931.239.349.540.951.71232.541.036.747.138.750.11331.240.134.845.535.847.01428.937.832.443.132.943.11527.135.930.541.332.943.11625.634.728.038.87.01428.937.828.038.87.01527.135.930.541.332.943.11625.634.728.038.87.01724.834.1 </th <th></th> <th colspan="13">Period of diagnosis</th>		Period of diagnosis												
Yearsobs. %rel. %obs. %rel. %obs. %rel. %0100.0100.0100.0100.0100.0100.0183.385.281.283.277.679.9272.675.773.376.769.873.4366.270.567.772.565.970.8460.866.063.869.761.767.8555.060.958.365.258.165.3650.456.754.662.254.962.9745.952.751.660.051.960.6842.749.947.456.349.859.4940.147.844.053.346.456.41037.945.931.239.349.540.951.71232.541.036.747.138.750.11331.240.134.845.535.847.01428.937.832.443.132.943.11527.135.930.541.332.943.11625.634.728.038.8111724.834.126.637.6111823.132.325.236.0111921.430.523.834.711		1978-	1987	1988-	-1997	199	1998+							
0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 1 83.3 85.2 81.2 83.2 77.6 79.9 2 72.6 75.7 73.3 76.7 69.8 73.4 3 66.2 70.5 67.7 72.5 65.9 70.8 4 60.8 66.0 63.8 69.7 61.7 67.8 5 55.0 60.9 58.3 65.2 58.1 65.3 6 50.4 56.7 54.6 62.2 54.9 62.9 7 45.9 52.7 51.6 60.0 51.9 60.6 8 42.7 49.9 47.4 56.3 49.8 59.4 9 40.1 47.8 44.0 53.3 46.4 56.4 10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9		n=6	528	n=1	,376	n=3	,758							
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Years	s obs. %	rel. %	obs. %	rel. %	obs. %	rel. %							
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0	100.0	100.0	100.0	100.0	100.0	100.0							
3 66.2 70.5 67.7 72.5 65.9 70.8 4 60.8 66.0 63.8 69.7 61.7 67.8 5 55.0 60.9 58.3 65.2 58.1 65.3 6 50.4 56.7 54.6 62.2 54.9 62.9 7 45.9 52.7 51.6 60.0 51.9 60.6 8 42.7 49.9 47.4 56.3 49.8 59.4 9 40.1 47.8 44.0 53.3 46.4 56.4 10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1	1	83.3	85.2	81.2	83.2	77.6	79.9							
4 60.8 66.0 63.8 69.7 61.7 67.8 5 55.0 60.9 58.3 65.2 58.1 65.3 6 50.4 56.7 54.6 62.2 54.9 62.9 7 45.9 52.7 51.6 60.0 51.9 60.6 8 42.7 49.9 47.4 56.3 49.8 59.4 9 40.1 47.8 44.0 53.3 46.4 56.4 10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1 15 27.1 35.9 30.5 41.3 32.9 43.1 16 25.6 34.7 28.0 38.8 17 24.8 3	2	72.6	75.7	73.3	76.7	69.8	73.4							
5 55.0 60.9 58.3 65.2 58.1 65.3 6 50.4 56.7 54.6 62.2 54.9 62.9 7 45.9 52.7 51.6 60.0 51.9 60.6 8 42.7 49.9 47.4 56.3 49.8 59.4 9 40.1 47.8 44.0 53.3 46.4 56.4 10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1 15 27.1 35.9 30.5 41.3 14.3 16 25.6 34.7 28.0 38.8 17 17 24.8 34.1 26.6 37.6 18 18 23.1 32.3<	3	66.2	70.5	67.7	72.5	65.9	70.8							
6 50.4 56.7 54.6 62.2 54.9 62.9 7 45.9 52.7 51.6 60.0 51.9 60.6 8 42.7 49.9 47.4 56.3 49.8 59.4 9 40.1 47.8 44.0 53.3 46.4 56.4 10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1 15 27.1 35.9 30.5 41.3 14.1 15 27.1 35.9 30.5 41.3 14.1 16 25.6 34.7 28.0 38.8 17 24.8 34.1 26.6 37.6 18 23.1 32.3 25.2 36.0 14.7 <td< td=""><td>4</td><td>60.8</td><td>66.0</td><td>63.8</td><td>69.7</td><td>61.7</td><td>67.8</td></td<>	4	60.8	66.0	63.8	69.7	61.7	67.8							
7 45.9 52.7 51.6 60.0 51.9 60.6 8 42.7 49.9 47.4 56.3 49.8 59.4 9 40.1 47.8 44.0 53.3 46.4 56.4 10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1 15 27.1 35.9 30.5 41.3 14.3 14.3 16 25.6 34.7 28.0 38.8 17 24.8 34.1 26.6 37.6 18 23.1 32.3 25.2 36.0 14.3 14.7 14.3 14.3 14.3	5	55.0	60.9	58.3	65.2	58.1	65.3							
7 45.9 52.7 51.6 60.0 51.9 60.6 8 42.7 49.9 47.4 56.3 49.8 59.4 9 40.1 47.8 44.0 53.3 46.4 56.4 10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1 15 27.1 35.9 30.5 41.3 1.4 1.4 16 25.6 34.7 28.0 38.8 1.7 1.4	6	50.4	56.7	54.6	62.2	54.9	62.9							
9 40.1 47.8 44.0 53.3 46.4 56.4 10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1 15 27.1 35.9 30.5 41.3 14.3 14.3 16 25.6 34.7 28.0 38.8 17 24.8 34.1 26.6 37.6 18 23.1 32.3 25.2 36.0 14.3	7	45.9	52.7	51.6	60.0	51.9	60.6							
10 37.9 45.9 41.9 51.8 43.2 53.5 11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1 15 27.1 35.9 30.5 41.3 43.1 32.9 43.1 16 25.6 34.7 28.0 38.8 17 24.8 34.1 26.6 37.6 18 23.1 32.3 25.2 36.0 14.3	8	42.7	49.9	47.4	56.3	49.8	59.4							
11 34.9 43.2 39.3 49.5 40.9 51.7 12 32.5 41.0 36.7 47.1 38.7 50.1 13 31.2 40.1 34.8 45.5 35.8 47.0 14 28.9 37.8 32.4 43.1 32.9 43.1 15 27.1 35.9 30.5 41.3 16 25.6 34.7 28.0 38.8 17 24.8 34.1 26.6 37.6 16 16 25.1 32.3 25.2 36.0 16 18 23.1 32.3 25.2 36.0 16 14 30.5 23.8 34.7	9	40.1	47.8	44.0	53.3	46.4	56.4							
1232.541.036.747.138.750.11331.240.134.845.535.847.01428.937.832.443.132.943.11527.135.930.541.3161625.634.728.038.8171724.834.126.637.6181823.132.325.236.0191921.430.523.834.7	10	37.9	45.9	41.9	51.8	43.2	53.5							
1331.240.134.845.535.847.01428.937.832.443.132.943.11527.135.930.541.3161625.634.728.038.8171724.834.126.637.6181823.132.325.236.0191921.430.523.834.7	11	34.9	43.2	39.3	49.5	40.9	51.7							
1428.937.832.443.132.943.11527.135.930.541.31625.634.728.038.81724.834.126.637.61823.132.325.236.01921.430.523.834.7	12	32.5	41.0	36.7	47.1	38.7	50.1							
1527.135.930.541.31625.634.728.038.81724.834.126.637.61823.132.325.236.01921.430.523.834.7	13	31.2	40.1	34.8	45.5	35.8	47.0							
1625.634.728.038.81724.834.126.637.61823.132.325.236.01921.430.523.834.7	14	28.9	37.8	32.4	43.1	32.9	43.1							
1724.834.126.637.61823.132.325.236.01921.430.523.834.7	15	27.1	35.9	30.5	41.3									
1823.132.325.236.01921.430.523.834.7	16	25.6	34.7	28.0	38.8									
19 21.4 30.5 23.8 34.7	17	24.8	34.1	26.6	37.6									
	18	23.1	32.3	25.2	36.0									
20 19.8 28.7 21.8 32.5	19	21.4	30.5	23.8	34.7									
	20	19.8	28.7	21.8	32.5									

Table 1b. Observed (obs.) and relative (rel.) survival of patients with nHL by period of diagnosis for period 1978-2011 (N=5,762).




Figure 2a. Survival of patients with nHL by gender. Included in the evaluation are 5,134 cases diagnosed between 1988 and 2011.

	G	Sender	r		
	Ma	ale	Ferr	nale	
	n=2,	651	n=2,483		
Years	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	
1	78.0	80.2	79.2	81.4	
2	69.3	72.9	72.2	75.8	
3	64.7	69.7	68.0	72.8	
4	60.5	66.6	64.1	70.0	
5	56.1	63.2	59.9	66.8	
6	52.8	60.8	56.2	63.9	
7	49.9	58.6	53.1	61.6	
8	46.6	55.9	50.1	59.3	
9	42.8	52.4	47.1	56.7	
10	40.1	50.1	44.9	55.1	
11	37.7	48.0	42.3	52.9	
12	35.1	45.7	39.8	50.7	
13	33.5	44.4	37.2	48.2	
14	31.3	42.3	34.4	45.3	
15	29.7	41.2	31.6	42.3	
16	27.2	38.5	29.2	40.0	
17	26.2	37.9	27.2	38.0	
18	23.7	35.1	26.8	37.5	
19	23.7	35.1	24.0	34.1	
20	23.1	34.9	20.6	30.0	
	0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Ma Years obs. % 0 100.0 1 78.0 2 69.3 3 64.7 4 60.5 5 56.1 6 52.8 7 49.9 8 46.6 9 42.8 10 40.1 11 37.7 12 35.1 13 33.5 14 31.3 15 29.7 16 27.2 17 26.2 18 23.7 19 23.7	Male Years obs. % rel. % O 100.0 100.0 1 78.0 80.2 Q 69.3 72.9 3 64.7 69.7 4 60.5 66.6 5 56.1 63.2 6 52.8 60.8 7 49.9 58.6 8 46.6 55.9 9 42.8 52.4 10 40.1 50.1 11 37.7 48.0 12 35.1 45.7 13 33.5 44.4 14 31.3 42.3 15 29.7 41.2 16 27.2 38.5 17 26.2 37.9 18 23.7 35.1 19 23.7 35.1	n=2,651 n=2, obs.% n=2, obs.% 100.0 100.0 100.0 1 78.0 80.2 79.2 2 69.3 72.9 72.2 3 64.7 69.7 68.0 4 60.5 66.6 64.1 5 56.1 63.2 59.9 6 52.8 60.8 56.2 7 49.9 58.6 53.1 8 46.6 55.9 50.1 9 42.8 52.4 47.1 10 40.1 50.1 44.9 11 37.7 48.0 42.3 12 35.1 45.7 39.8 13 33.5 44.4 37.2 14 31.3 42.3 34.4 15 29.7 41.2 31.6 14 31.3 42.3 34.4 15 29.7 38.5 29.2 17 26.2 37.9	

Table 2b. Observed (obs.) and relative (rel.) survival of patients with nHL by gender for period 1988-2011 (N=5,134).





Figure 2c. Conditional relative 2 / 5-year survival of patients with nHL by gender. For 5,134 of 5,134 cases diagnosed between 1988 and 2011 valid data could be obtained for this item.

		G	Gender			
		Male		F	emale	
		Cond. s	surv. %		Cond. s	surv. %
Years	n	2 yrs	5 yrs	n	2 yrs	5 yrs
0	2,651	72.9	63.2	2,483	75.8	66.8
1	1,962	87.0	76.1	1,880	89.6	78.9
2	1,579	91.6	80.9	1,593	92.7	81.9
3	1,336	91.1	81.0	1,371	92.3	82.3
4	1,117	91.9	79.7	1,161	91.9	82.1
5	922	93.3	80.5	963	93.0	83.9
6	763	92.6	80.4	806	93.6	84.2
7	655	90.2	79.6	694	93.0	84.1
8	549	90.6	81.3	588	94.0	83.2
9	456	92.6	82.8	488	94.4	82.0
10	374	92.4	84.6	403	93.3	78.8



Conditional relative survival rates refer to the relative survival probability, in this case for 2 and 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 2a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup gender="Male", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 91.1% (n=1,336).




Figure 3a. Relative survival of patients with nHL by age category. Included in the evaluation are 5,134 cases diagnosed between 1988 and 2011.




Figure 3b. Observed survival of patients with nHL by age category. Included in the evaluation are 5,134 cases diagnosed between 1988 and 2011.

					Age	categ	ory				
		0-49	yrs	50-59	9 yrs	60-69	60-69 yrs 70-7			80+ yrs n=662	
		n=1,	035	n=9	952	n=1,276		n=1,209			
	Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
	0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
	1	88.1	88.2	87.1	87.6	84.0	85.2	71.5	74.2	53.8	60.0
	2	82.4	82.6	80.9	81.9	76.8	79.0	62.4	67.2	41.0	51.2
	3	80.0	80.4	77.9	79.3	72.8	76.2	55.5	62.4	34.7	48.3
	4	77.6	78.2	74.3	76.3	67.6	71.9	51.1	60.1	29.7	46.3
	5	75.7	76.4	71.2	73.7	63.4	68.8	44.4	55.0	23.8	42.6
	6	74.3	75.1	66.7	69.7	59.6	65.9	40.4	52.8	19.6	40.8
	7	72.2	73.3	63.4	66.9	56.7	64.1	36.8	51.0	15.4	36.7
	8	70.6	71.7	62.1	66.0	52.9	61.3	30.5	45.2	12.9	33.8
	9	68.8	70.2	56.8	61.1	50.2	59.6	25.8	40.7	10.2	33.8
	10	67.6	69.2	53.4	58.1	46.2	56.8	23.1	39.4	9.6	33.8
	11	66.3	68.0	51.0	56.0	43.1	54.5	19.4	35.9		
	12	64.0	66.0	49.1	54.8	40.9	53.1	15.6	31.8		
	13	62.0	64.2	46.7	52.6	37.9	51.5	13.4	29.7		
	14	60.1	62.4	44.8	51.2	33.4	47.4	10.9	27.5		
	15	58.3	60.7	41.7	48.5	29.7	43.8	10.9	27.5		
	16	57.3	59.9	39.8	47.2	24.1	38.2				
	17	54.6	57.5	38.1	46.1	23.3	38.2				
	18	52.9	55.9	36.8	45.2	19.8	33.6				
	19	52.9	55.3	34.7	43.6	16.5	29.4				
	20	50.0	53.7								

Table 3c. Observed (obs.) and relative (rel.) survival of patients with nHL by age category for period 1988-2011 (N=5,134).




Figure 4a. Relative survival of patients with nHL by Ann Arbor staging. For 2,608 of 5,134 cases diagnosed between 1988 and 2011 valid data could be obtained for this item. For a total of 2,603 cases an evaluable classification was established. The grey line represents the subgroup of 2,531 patients with missing values regarding Ann Arbor staging (49.3% of 5,134 patients, the percent values of all other categories are related to n=2,603).

		Ann Arbor staging											
	I		I	l	III		IV		NA				
	n=6	652	n=542		n=466		n=943		n=2,531				
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %			
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0			
1	93.4	95.3	86.3	88.3	85.3	87.0	79.9	81.4	71.3	73.8			
2	87.5	91.0	79.6	83.0	78.5	81.5	71.1	73.6	62.8	66.8			
3	85.0	90.1	76.5	81.3	71.9	75.7	66.8	70.2	58.0	63.2			
4	82.1	89.1	73.3	79.3	66.8	72.0	60.7	64.9	54.3	60.7			
5	79.0	87.7	69.0	76.0	63.7	69.6	55.4	60.3	50.0	57.3			
6	75.7	85.9	67.5	75.3	60.8	67.6	50.1	55.3	46.6	54.8			
7	73.6	85.0	64.7	73.9	57.5	64.8	45.6	51.3	43.9	52.7			
8	71.0	83.8	60.4	70.1	56.6	64.7	42.4	48.3	40.4	49.8			
9	68.1	82.2	57.8	67.9	52.5	61.2	39.5	45.8	36.6	46.1			
10	65.1	80.0	54.7	65.5	50.0	59.6	38.0	44.6	34.0	43.9			
11	62.5	78.6	53.6	65.1	46.7	56.4	36.3	43.1	31.0	40.8			
12	58.6	75.5	53.1	65.1	45.7	55.8	32.8	40.0	28.5	38.3			
13	55.1	72.6	51.6	64.6	45.7	55.8	31.5	38.6	26.0	35.7			
14	51.8	69.0	50.8	64.4	45.7	55.8	28.1	35.3	23.3	32.6			
15	49.4	67.2	47.1	60.5	42.9	53.2	25.9	33.2	21.6	31.0			
16	44.9	63.1	42.6	56.3	39.7	49.4	24.6	32.1	19.9	29.3			
17	44.9	63.1	42.6	55.6	34.1	44.2	23.6	31.3	17.9	27.0			
18	43.7	62.8	37.2	49.9	34.1	43.0	21.3	28.4	17.3	26.0			
19	41.7	62.4	37.2	46.0	34.1	41.7			16.1	24.9			
20	41.7	60.5	37.2	42.2					13.7	22.0			

Table 4b. Observed (obs.) and relative (rel.) survival of patients with nHL by Ann Arbor staging for period 1988-2011 (N=2,603).




Figure 4c. Relative survival of patients with nHL by Ann Arbor staging. For 1,792 of 3,758 cases diagnosed between 1998 and 2011 valid data could be obtained for this item. For a total of 1,788 cases an evaluable classification was established. The grey line represents the subgroup of 1,970 patients with missing values regarding Ann Arbor staging (52.4% of 3,758 patients, the percent values of all other categories are related to n=1,788).

Ann Arbor staging												
	I		I	I	II	I	IV		NA			
	n=4	05	n=3	861	n=3	345	n=6	677	n=1,970			
Years	obs. %	rel. %	obs. %	rel. %								
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0		
1	95.3	97.2	86.9	89.0	87.2	89.0	80.9	82.5	69.5	71.9		
2	92.0	95.4	81.2	84.7	80.7	84.0	72.0	74.8	60.3	64.1		
3	89.4	94.4	79.4	83.8	75.3	79.9	68.3	72.0	56.0	61.0		
4	87.1	93.7	76.0	81.9	69.7	75.8	62.4	67.1	52.1	58.2		
5	84.8	93.0	73.6	80.7	67.0	73.9	57.2	62.5	48.7	55.7		
6	83.1	93.0	72.3	80.6	65.1	73.3	52.1	57.6	45.2	53.1		
7	80.2	91.3	69.9	79.6	62.2	71.0	47.2	53.3	42.7	51.1		
8	78.6	90.6	65.5	75.8	61.3	71.0	45.9	52.3	40.4	49.6		
9	76.6	90.5	62.8	73.0	56.8	67.9	43.6	50.7	36.4	45.7		
10	72.8	88.1	58.4	69.9	55.2	66.2	40.2	47.1	33.4	42.7		
11	71.3	87.5	58.4	69.2			38.8	45.6	30.8	39.9		
12	64.0	80.0	55.5	66.0			37.2	43.9	29.4	39.1		
13	64.0	77.2					37.2	42.4	25.6	34.1		

Table 4d. Observed (obs.) and relative (rel.) survival of patients with nHL by Ann Arbor staging for period 1998-2011 (N=1,788).




Figure 5a. Observed post-progression survival of 1,879 patients with nHL diagnosed between 1978 and 2011 (incl. M1). These 1,879 patients with documented progression events during their course of disease represent 32.6% of the totally 5,762 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=799, 13.9%).

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "All types" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

	Type of ogression
	All types
	n=1,879
Months	%
0	100.0
12	66.0
24	55.0
36	47.5
48	42.5
60	39.3

Table 5b. Observed post-progression survival of patients with nHL for period 1978-2011 (N=1,879).

Shortcuts

AS Assembled survival chart (observed, expected, relative) CS Conditional survival DCO Death certificate only. The death certificate provides the only notification to the registry. Munich Cancer Registry, Germany (Tumorregister München) MCR Not available NA NCI National Cancer Institute, USA NOS Not otherwise specified Observed/overall survival (Kaplan-Meier estimate) OS PPS Post-progression survival RS Relative Survival. Ratio of observed and expected survival (derived from the normal population) SEER Surveillance, Epidemiology, and End Results, USA TTP Time to progression Date of entry: Date of diagnosis Event (Progression): First local recurrence, lymph node relapse or distant metastasis, unspecified recurrence First all-cause recurrence is illustrated by survival curves (Kaplan-Meier estimate). First local recurrence, lymph node relapse or distant metastasis are depicted cumulatively, where applicable ("reverse" Kaplan-Meier estimate). UICC Union for International Cancer Control, Geneva

Recommended Citation

Munich Cancer Registry. Survival C82-C85: NHL [Internet]. 2013 [updated 2013 Apr 1; cited 2013 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_C8285E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Munich Cancer Registry

Index of figures and tables

Fig./Tb	pl.	Page
1a	Relative survival by period of diagnosis (chart)	2
1b	Survival by period of diagnosis (table)	3
2a	Survival by gender (chart)	3
2b	Survival by gender (table)	4
2c	Conditional survival by gender (chart)	4
2d	Conditional survival by gender (table)	5
3a	Relative survival by age category (chart)	5
3b	Observed survival by age category (chart)	6
3c	Survival by age category (table)	6
4a	Relative survival by Ann Arbor staging 1988+ (chart)	7
4b	Survival by Ann Arbor staging 1988+ (table)	7
4c	Relative survival by Ann Arbor staging 1998+ (chart)	8
4d	Survival by Ann Arbor staging 1998+ (table)	8
5a	Observed post-progression survival (chart)	9
5b	Observed post-progression survival (table)	9